Fulltext

Cardiovascular Disease and Use of Renin-Angiotensin System Inhibitors in COVID-19

Kow CS 1 , Zaidi STR 2 , Hasan SS 3

Affiliations 

  • 1 Faculty of Medicine and Health Sciences, International Medical University, Kuala Lumpur, Malaysia
  • 2 School of Healthcare, University of Leeds, Leeds, UK
  • 3 School of Applied Sciences, University of Huddersfield, Huddersfield, UK. s.hasan@hud.ac.uk
Am J Cardiovasc Drugs, 2020 Jun;20(3):217-221.
PMID: 32281055 DOI: 10.1007/s40256-020-00406-0

Abstract

There is ongoing debate on the safety of renin-angiotensin system (RAS) inhibitors in COVID-19. Recently published studies highlight a potential relationship between cardiovascular disease (CVD) and COVID-19. This article aims to summarize the evidence on the use of RAS inhibitors in CVD patients with COVID-19, focusing on safety issues of the RAS inhibitors and their relationship with COVID-19.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications